Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.82 |
| ▸ | TP53 | P04637 | 3/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | HPGD | P15428 | 2/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.74 |
| ▸ | RELA | Q04206 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28788159 | 0.91 | KDM4E (0.83) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| 5,7-Dimethoxyisoflavone SCHEMBL1675985 | 0.90 | ALDH1A1 (1.00) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL30288208 | 0.89 | CYP3A4 (0.81) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL13640733 | 0.89 | CYP3A4 (0.81) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL1743412 | 0.88 | ALDH1A1 (0.79) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL26145339 | 0.88 | KDM4E (0.85) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL5624288 | 0.88 | CYP3A4 (0.79) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL7056427 | 0.86 | CYP3A4 (0.76) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL5623038 | 0.86 | CYP3A4 (0.76) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A | |
| SCHEMBL16335756 | 0.86 | CYP3A4 (0.75) | CYP3A4KDM4EALDH1A1HSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIVERSITÄT REGENSBURG (AT) | 2023-05-18 | — | — | US | disclosed |
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | UNIVERSITÄT REGENSBURG (AT) | 2023-05-18 | — | — | US | disclosed |
| US-8742141-B2 | Inhibition and treatment of prostate cancer metastasis | NORTHWESTERN UNIVERSITY (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130296582-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-07 | — | — | US | disclosed |
| US-8481760-B2 | Inhibition and treatment of prostate cancer metastasis | NORTHWESTERN UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481760-B2 | Inhibition and treatment of prostate cancer metastasis | NORTHWESTERN UNIVERSITY (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120283313-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2010042933-A9 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010042933-A2 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20090124569-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124569-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009049214-A2 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2006030322-A2 | USE OF FLA VONE/FLA VANONE DERIVATIVES FN THE TREATMENT OR PREVENTION OF RESPIRATORY CONDITIONS | UNIVERSITY OF MANITOBA (CA) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296582-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885 |
| US-20230149344-A1 | BIOCHANIN A DERIVATIVES FOR TREATMENT OF BEST1-RELATED RETINOPATHIES | SORBS1, SLC5A6, SLC20A1 | CYP3A4 4678/4885KDM4E 2594/4885ALDH1A1 928/4885 |
| US-20120283313-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885 |
| US-20090124569-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885 |
| US-20100137425-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | CYP3A4 557/4885KDM4E 242/4885ALDH1A1 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.